Tay-Sachs Disease: A Concise Overview of This Genetic Disorder
Tay-Sachs disease (TSD) is a rare, fatal autosomal recessive neurodegenerative disorder caused by deficiency of β-hexosaminidase A (HexA), leading to GM2 ganglioside accumulation in neurons.
Key Facts
- Gene: HEXA (15q23-q24); >200 pathogenic variants.
- Inheritance: Autosomal recessive; carrier frequency ~1/30 Ashkenazi Jewish, 1/250 general.
- Forms: Classic infantile (onset 3–6 mo, death by 4–5), Juvenile (2–10 yr), Late-onset (adolescence+).
- Hallmark: Cherry-red spot on macula (infantile).
- Symptoms: Developmental regression, hypotonia→spasticity, seizures, blindness, dysphagia.
- Diagnosis: HexA enzyme assay (leukocytes) + HEXA sequencing.
- Treatment: Supportive only (seizure control, nutrition, respiratory, palliative). No disease-modifying therapy yet.
- Research: Gene therapy (AAV-HEXA), substrate reduction, pharmacological chaperones, enzyme replacement.
- Prevention: Carrier screening (enzyme + DNA), prenatal diagnosis, PGT-M.
Historical Note
Named for Warren Tay (1881, cherry-red spot) and Bernard Sachs (1887, cellular pathology + Ashkenazi predilection). Not related to any famous affected individuals — it is uniformly fatal in infancy without exception in classic form.
TSD exemplifies the power of carrier screening to prevent a devastating genetic disease.
Eating Disorders - Related Articles
- Dysphagia Solutions: Adaptive Equipment & Management
- Binge Eating Disorder: Health Risks and the Path to Recovery
- Betrayal and Emotional Eating: Understanding the Connection
- Eating Disorders in Men vs. Women: Prevalence, Risk Groups & Underdiagnosis
- Understanding Eating Disorders: Types, Symptoms & Treatment
- "Eat Me": Multifaceted Meanings from Literal to Metaphorical
- Understanding Taste Alterations: Causes, Red Flags, and Management
